Our PipelineFocus on Nomethiazoles for improvement of cognitive function

Revivo has three candidate compounds under development for Alzheimer’s and other diseases of cognitive impairment. RIV-1061 has been evaluated in a prior Phase 1 study and is now returning to the clinic for development. Other compounds in the pipeline are targeted for Alzheimer’s disease or other neurodegenerative diseases leading to cognitive dysfunction.